LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

Search

Bruker Corp

Fermé

SecteurSoins de santé

40.5 -0.54

Résumé

Variation du prix de l'action

24h

Actuel

Min

39.78

Max

42.95

Chiffres clés

By Trading Economics

Revenu

-27M

14M

Ventes

115M

980M

P/E

Moyenne du Secteur

53.211

54.379

BPA

0.76

Rendement du dividende

0.49

Marge bénéficiaire

1.419

Employés

11,396

EBITDA

-7.8M

125M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+53.36% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.49%

2.55%

Prochains Résultats

5 août 2025

Date du Prochain Dividende

16 juin 2025

Date du Prochain Détachement de Dividende

30 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-2.7B

6.1B

Ouverture précédente

41.04

Clôture précédente

40.5

Sentiment de l'Actualité

By Acuity

50%

50%

195 / 382 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Bruker Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 mai 2025, 23:59 UTC

Actualités
Résultats

Naver 1Q Net Slumps on Higher Costs

8 mai 2025, 23:39 UTC

Résultats

OCBC 1Q Net Down on Lower Interest Income

8 mai 2025, 23:01 UTC

Résultats

Macquarie Raises Dividend After 5.5% Rise in Annual Profit -- Update

8 mai 2025, 22:52 UTC

Résultats

REA Expects Annual Listings Growth Despite April Decline

8 mai 2025, 22:46 UTC

Résultats

Macquarie Raises Dividend After 5.5% Rise in Annual Profit

8 mai 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

8 mai 2025, 23:45 UTC

Market Talk

Nikkei May Rise as Tariffs Fears Ease -- Market Talk

8 mai 2025, 23:41 UTC

Market Talk

Gold Rises on Possible Technical Recovery; Gains May be Capped by Risk-on Mood -- Market Talk

8 mai 2025, 23:30 UTC

Résultats

Itau Unibanco 1Q Rev BRL45.02B >ITUB

8 mai 2025, 23:29 UTC

Résultats

Itau Unibanco 1Q EPS BRL1.03 >ITUB

8 mai 2025, 23:22 UTC

Résultats

Naver 1Q Net Profit Largely Met FactSet-Compiled Consensus

8 mai 2025, 23:22 UTC

Résultats

Naver 1Q Net KRW423.70B Vs. Net KRW555.80B >035420.SE

8 mai 2025, 23:21 UTC

Résultats

Naver 1Q Oper Pft KRW505.30B Vs. Pft KRW439.30B >035420.SE

8 mai 2025, 23:21 UTC

Résultats

Naver 1Q Rev KRW2.787T Vs. KRW2.526T >035420.SE

8 mai 2025, 23:17 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.35B Vs. S$2.44B >O39.SG

8 mai 2025, 23:17 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Total Income S$3.66B Vs. S$3.63B >O39.SG

8 mai 2025, 23:17 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Net S$1.88B Vs. Net S$1.98B >O39.SG

8 mai 2025, 23:05 UTC

Market Talk

ANZ Could Cut Dividend by 10% From 2H -- Market Talk

8 mai 2025, 23:05 UTC

Market Talk

Global Equities Roundup: Market Talk

8 mai 2025, 22:28 UTC

Résultats

REA Expects FY 2025 Listings Growth of 1-2%

8 mai 2025, 22:28 UTC

Résultats

REA Says April Listings Decline Reflects Year Ago Strength, Timing of Easter and Election

8 mai 2025, 22:27 UTC

Résultats

REA Says April Sydney, Melbourne Listings Both Down 16% on Year

8 mai 2025, 22:27 UTC

Résultats

REA Says April Residential Listings Fell by 11% on Year

8 mai 2025, 22:26 UTC

Résultats

REA 3Q Operating Expenses A$176 Million, Up 12% on Year

8 mai 2025, 22:26 UTC

Résultats

REA 3Q Free Cash Flow A$132 Million, Up 19% on Year

8 mai 2025, 22:26 UTC

Résultats

REA 3Q Operating Ebitda A$199 Million, Up 12% on Year

8 mai 2025, 22:26 UTC

Résultats

REA Nine-Months Free Cash Flow A$389 Million, Up 21% on Year

8 mai 2025, 22:25 UTC

Résultats

REA Nine-Months Operating Expenses A$513 Million, Up 15% on Year

8 mai 2025, 22:25 UTC

Résultats

REA Nine-Months Operating Ebitda A$734 Million, Up 19% on Year

8 mai 2025, 22:25 UTC

Résultats

REA 3Q Revenue A$374 Million, Up 12% on Year

Comparaison

Variation de prix

Bruker Corp prévision

Objectif de Prix

By TipRanks

53.36% hausse

Prévisions sur 12 Mois

Moyen 60.5 USD  53.36%

Haut 80 USD

Bas 45 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

10 ratings

7

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

38.97 / 40.93Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

195 / 382Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Bruker Corp

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.